Emergence of resistance to tyrosine kinase inhibitors in non-small-cell lung cancer can be delayed by an upfront combination with the HSP90 inhibitor onalespib

BACKGROUND: Tyrosine kinase inhibitors, such as crizotinib and erlotinib, are widely used to treat non-small-cell lung cancer, but after initial response, relapse is common because of the emergence of resistance through multiple mechanisms. Here, we investigated whether a frontline combination with...

Descripción completa

Detalles Bibliográficos
Autores principales: Courtin, Aurelie, Smyth, Tomoko, Hearn, Keisha, Saini, Harpreet K, Thompson, Neil T, Lyons, John F, Wallis, Nicola G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5117788/
https://www.ncbi.nlm.nih.gov/pubmed/27673365
http://dx.doi.org/10.1038/bjc.2016.294

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5117788/
https://www.ncbi.nlm.nih.gov/pubmed/27673365
http://dx.doi.org/10.1038/bjc.2016.294

Ejemplares similares